{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T09:56:23Z","timestamp":1790589383322,"version":"4.1.0"},"reference-count":78,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"name":"Science Fund for Distinguished Young Scholars of Shaanxi Province","award":["2024JC-JCQN-29"],"award-info":[{"award-number":["2024JC-JCQN-29"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62072377"],"award-info":[{"award-number":["62072377"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Endometrial carcinoma (EC) is a type of cancer that originates in the lining\nof the uterus, known as the endometrium. It is associated with various treatment options such\nas surgery, radiation therapy, chemotherapy, and hormone therapy, each presenting unique challenges\nand limitations. Beta-catenin, a protein involved in the development and progression of several\ncancers, including EC, plays a crucial role. Abnormal beta-catenin signaling is often linked to\nthe emergence of specific EC subtypes, affecting tumor growth and invasion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The study's objective is to identify compounds targeting the beta-catenin protein for\ntreating endometrial cancer (EC) using in silico drug design. Our approach includes molecular\ndocking to evaluate binding affinities, ADME profiling for pharmacokinetic properties, toxicity assessments,\nand molecular dynamics simulations to assess compound stability and interactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Approximately one thousand anti-cancer phytochemicals were sourced from PubChem\nand subjected to molecular docking simulations against the beta-catenin protein. The compounds\nwere evaluated based on their binding affinities, with the top five selected for further analysis. These\nfive molecules underwent toxicity and ADME profiling. The Prediction of Activity Spectra\nfor Substances (PASS) tool was used to identify compounds targeting CTNNB1. Comparative\nmolecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA)\nwere employed to establish quantitative structure-activity relationship (QSAR) models for the\nfive CTNNB1 antagonist molecules.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The selected five compounds, namely Pazopanib, Binimetinib, Telatinib, 4-(2,3-Dihydrobenzo[\nb][1,4]dioxin-6-yl)-3-((5-nitrothiazol-2-yl)thio)-1H-1,2,4-triazol-5(4H)-one, and Ribavirin,\ndemonstrated efficacy against CTNN1. MD simulations of the docked complexes confirmed\nthe stability of these drugs in binding to the target protein. All five molecules showed\npromising safety and effectiveness profiles according to their ADME and toxicity evaluations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Through a comprehensive screening process employing in silico drug design methods,\nthis study successfully identified five potential human anticancer drug candidates targeting\nthe beta-catenin protein. These findings offer a foundation for further experimental validation and\ndevelopment towards the treatment of EC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0109298673307257240826111754","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:58:12Z","timestamp":1727247492000},"page":"1383-1404","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Discovery of Small Molecule Inhibitors Targeting CTNNB1 (\u03b2-catenin) for Endometrial cancer: Employing 3D QSAR, Drug-Likeness Assessment, ADMET Predictions, Molecular Docking and Simulation"],"prefix":"10.2174","volume":"33","author":[{"given":"Israr","family":"Fatima","sequence":"first","affiliation":[{"name":"Center of Bioinformatics, College of Life Sciences, NorthWest Agriculture and Forestry University, Yangling,Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Center of Bioinformatics, College of Life Sciences, NorthWest Agriculture and Forestry University, Yangling,Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[{"name":"Center of Bioinformatics, College of Life Sciences, NorthWest Agriculture and Forestry University, Yangling,Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"He","sequence":"additional","affiliation":[{"name":"Center of Bioinformatics, College of Life Sciences, NorthWest Agriculture and Forestry University, Yangling,Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Liao","sequence":"additional","affiliation":[{"name":"Center of Bioinformatics, College of Life Sciences, NorthWest Agriculture and Forestry University, Yangling,Shaanxi, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1002\/cncr.32802.","volume":"126","author":"Henley S. J.","year":"2020","unstructured":"Henley S. J.; Ward E. M.; Scott S.; Ma J.; Anderson R. N.; Firth A. U.; Thomas C. C.; Islami F.; Weir H. K.; Lewis D. R. J. C.; Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer  2020,126(10),2225-2249","journal-title":"Cancer"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"d3954","DOI":"10.1136\/bmj.d3954","volume":"343","author":"Saso S.","year":"2011","unstructured":"Saso S.; Chatterjee J.; Georgiou E.; Ditri A.M.; Smith J.R.; Ghaem-Maghami S.; Endometrial cancer. BMJ  2011,343(jul06 2),d3954","journal-title":"BMJ"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"154411","DOI":"10.1016\/j.prp.2023.154411","volume":"244","author":"Abdelmaksoud N.M.","year":"2023","unstructured":"Abdelmaksoud N.M.; El-Mahdy H.A.; Ismail A.; Elsakka E.G.E.; El-Husseiny A.A.; Khidr E.G.; Ali E.M.; Rashed M.H.; El-Demerdash F.E.S.; Doghish A.S.; The role of miRNAs in the pathogenesis and therapeutic resistance of endometrial cancer: A spotlight on the convergence of signaling pathways. Pathol Res Pract  2023,244,154411","journal-title":"Pathol Res Pract"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41568-019-0177-x","volume":"19","author":"Urick M.E.","year":"2019","unstructured":"Urick M.E.; Bell D.W.; Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer  2019,19(9),510-521","journal-title":"Nat Rev Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/modpathol.2016.135","volume":"29","author":"Ring K.L.","year":"2016","unstructured":"Ring K.L.; Bruegl A.S.; Allen B.A.; Elkin E.P.; Singh N.; Hartman A.R.; Daniels M.S.; Broaddus R.R.; Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol  2016,29(11),1381-1389","journal-title":"Mod Pathol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2009.07.039","volume":"137","author":"Stoffel E.","year":"2009","unstructured":"Stoffel E.; Mukherjee B.; Raymond V.M.; Tayob N.; Kastrinos F.; Sparr J.; Wang F.; Bandipalliam P.; Syngal S.; Gruber S.B.; Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology  2009,137(5),1621-1627","journal-title":"Gastroenterology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/GCO.0000000000000338","volume":"29","author":"Lee Y.C.","year":"2017","unstructured":"Lee Y.C.; Lheureux S.; Oza A.M.; Treatment strategies for endometrial cancer: current practice and perspective. Curr Opin Obstet Gynecol  2017,29(1),47-58","journal-title":"Curr Opin Obstet Gynecol"},{"key":"ref=8","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211035959","volume":"13","author":"Jamieson A.","year":"2021","unstructured":"Jamieson A.; Bosse T.; McAlpine J.N.; The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer. Ther Adv Med Oncol  2021,13","journal-title":"Ther Adv Med Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1080\/14656566.2019.1654996","volume":"20","author":"Neri M.","year":"2019","unstructured":"Neri M.; Peiretti M.; Melis G.B.; Piras B.; Vallerino V.; Paoletti A.M.; Madeddu C.; Scartozzi M.; Mais V.; Systemic therapy for the treatment of endometrial cancer. Expert Opin Pharmacother  2019,20(16),2019-2032","journal-title":"Expert Opin Pharmacother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40661-016-0035-4","volume":"3","author":"Talhouk A.","year":"2016","unstructured":"Talhouk A.; McAlpine J.N.; New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract  2016,3(1),14","journal-title":"Gynecol Oncol Res Pract"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/modpathol.2015.43","volume":"28","author":"Stelloo E.","year":"2015","unstructured":"Stelloo E.; Bosse T.; Nout R.A.; MacKay H.J.; Church D.N.; Nijman H.W.; Leary A.; Edmondson R.J.; Powell M.E.; Crosbie E.J.; Kitchener H.C.; Mileshkin L.; Pollock P.M.; Smit V.T.; Creutzberg C.L.; Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; A TransPORTEC initiative. Mod Pathol  2015,28(6),836-844","journal-title":"Mod Pathol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.3390\/ijms21124272","volume":"21","author":"McMellen A.","year":"2020","unstructured":"McMellen A.; Woodruff E. R.; Corr B. R.; Bitler B. G.; Moroney M. R.; Wnt signaling in gynecologic malignancies. Int J Mol Sci  2020,21(12),4272","journal-title":"Int J Mol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nature12113","volume":"497","author":"Levine D.A.","year":"2013","unstructured":"Levine D.A.; Schultz N.; Cherniack A.D.; Akbani R.; Liu Y.; Shen H.; Robertson A.G.; Pashtan I.; Shen R.; Benz C.C.; Yau C.; Laird P.W.; Ding L.; Zhang W.; Mills G.B.; Kucherlapati R.; Mardis E.R.; Levine D.A.; Integrated genomic characterization of endometrial carcinoma. Nature  2013,497(7447),67-73","journal-title":"Nature"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc3419","volume":"13","author":"Anastas J.N.","year":"2013","unstructured":"Anastas J.N.; Moon R.T.; WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer  2013,13(1),11-26","journal-title":"Nat Rev Cancer"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ijc.20609","volume":"113","author":"Dihlmann S.","year":"2005","unstructured":"Dihlmann S.; von Knebel Doeberitz M.; Wnt\/?-catenin- pathway as a molecular target for future anti-cancer therapeutics. Int J Cancer  2005,113(4),515-524","journal-title":"Int J Cancer"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nature03319","volume":"434","author":"Reya T.","year":"2005","unstructured":"Reya T.; Clevers H.; Wnt signalling in stem cells and cancer. Nature  2005,434(7035),843-850","journal-title":"Nature"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s00432-006-0179-4","volume":"133","author":"Konopka B.","year":"2007","unstructured":"Konopka B.; Janiec-Jankowska A.; Czapczak D.; Paszko Z.; Bidzi\u0144ski M.; Olszewski W.; Goluda C.; Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol  2007,133(6),361-371","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/PAI.0000000000000749","volume":"28","author":"Huang H.N.","year":"2020","unstructured":"Huang H.N.; Kuo C.W.; Lin M.C.; Mao T.L.; Kuo K.T.; Frequent CTNNB1 or PIK3CA mutations occurred in endometrial endometrioid adenocarcinoma with high levels of microsatellite instability and loss of MSH2\/MSH6 expression. Appl Immunohistochem Mol Morphol  2020,28(4),284-289","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1090788","DOI":"10.3389\/fmed.2022.1090788","volume":"9","author":"Weng C.H.","year":"2022","unstructured":"Weng C.H.; Wu K.Y.; Wang C.J.; Huang H.J.; Tsai C.L.; Lin C.Y.; Ro A.; Lai C.H.; Chao A.S.; Wu R.C.; Chao A.; Massively parallel sequencing of endometrial lavage specimens for the detection of cancer-associated mutations in atypical and non-atypical endometrial hyperplasia. Front Med (Lausanne)  2022,9,1090788","journal-title":"Front Med (Lausanne)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/his.12053","volume":"62","author":"Matias-Guiu X.","year":"2013","unstructured":"Matias-Guiu X.; Prat J.; Molecular pathology of endometrial carcinoma. Histopathology  2013,62(1),111-123","journal-title":"Histopathology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","volume":"180","author":"Dou Y.","year":"2020","unstructured":"Dou Y.; Kawaler E. A.; Zhou D. C.; Gritsenko M. A.; Huang C.; Blumenberg L.; Karpova A.; Petyuk V. A.; Savage S. R.; Satpathy S.; Proteogenomic characterization of endometrial carcinoma. Cell  2020,180(4),729-748.e26","journal-title":"Cell"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1007\/s11010-021-04174-6","volume":"476","author":"El Sabeh M.","year":"2021","unstructured":"El Sabeh M.; Saha S.K.; Afrin S.; Islam M.S.; Borahay M.A.; Wnt\/\u03b2-catenin signaling pathway in uterine leiomyoma: Role in tumor biology and targeting opportunities. Mol Cell Biochem  2021,476(9),3513-3536","journal-title":"Mol Cell Biochem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/854056","volume":"2015","author":"Kiewisz J.","year":"2015","unstructured":"Kiewisz J.; Wasniewski T.; Kmiec Z.; Participation of WNT and \u03b2-catenin in physiological and pathological endometrial changes: Association with angiogenesis. BioMed Res Int  2015,2015(1),1-11","journal-title":"BioMed Res Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","volume":"30","author":"Kurnit K.C.","year":"2017","unstructured":"Kurnit K.C.; Kim G.N.; Fellman B.M.; Urbauer D.L.; Mills G.B.; Zhang W.; Broaddus R.R.; CTNNB1 (beta- catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence. Mod Pathol  2017,30(7),1032-1041","journal-title":"Mod Pathol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.18632\/oncotarget.201","volume":"1","author":"Wang Y.","year":"2010","unstructured":"Wang Y.; van der Zee M.; Fodde R.; Blok L.J.; Wnt\/\u0392- catenin and sex hormone signaling in endometrial homeostasis and cancer. Oncotarget  2010,1(7),674-684","journal-title":"Oncotarget"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e23181","DOI":"10.4161\/spmg.23181","volume":"3","author":"Lombardi A.P.G.","year":"2013","unstructured":"Lombardi A.P.G.; Royer C.; Pisolato R.; Cavalcanti F.N.; Lucas T.F.G.; Lazari M.F.M.; Porto C.S.; Physiopathological aspects of the Wnt\/\u03b2-catenin signaling pathway in the male reproductive system. Spermatogenesis  2013,3(1),e23181","journal-title":"Spermatogenesis"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"a008052","DOI":"10.1101\/cshperspect.a008052","volume":"4","author":"Polakis P.","year":"2012","unstructured":"Polakis P.; Wnt signaling in cancer. Cold Spring Harb Perspect Biol  2012,4(5),a008052","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s11481-012-9417-5","volume":"7","author":"Inestrosa N.C.","year":"2012","unstructured":"Inestrosa N.C.; Montecinos-Oliva C.; Fuenzalida M.; Wnt signaling: Role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol  2012,7(4),788-807","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/labinvest.3700509","volume":"87","author":"Luo J.","year":"2007","unstructured":"Luo J.; Chen J.; Deng Z.L.; Luo X.; Song W.X.; Sharff K.A.; Tang N.; Haydon R.C.; Luu H.H.; He T.C.; Wnt signaling and human diseases: What are the therapeutic implications? Lab Invest  2007,87(2),97-103","journal-title":"Lab Invest"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12015-014-9515-2","volume":"10","author":"Ring A.","year":"2014","unstructured":"Ring A.; Kim Y.M.; Kahn M.; Wnt\/catenin signaling in adult stem cell physiology and disease. Stem Cell Rev  2014,10(4),512-525","journal-title":"Stem Cell Rev"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"C511","DOI":"10.1152\/ajpcell.00117.2015","volume":"309","author":"Novellasdemunt L.","year":"2015","unstructured":"Novellasdemunt L.; Antas P.; Li V.S.W.; Targeting Wnt signaling in colorectal cancer. A review in the theme: cell signaling: Proteins, pathways and mechanisms. Am J Physiol Cell Physiol  2015,309(8),C511-C521","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ceb.2007.09.014","volume":"19","author":"Prestwich T.C.","year":"2007","unstructured":"Prestwich T.C.; MacDougald O.A.; Wnt\/\u03b2-catenin signaling in adipogenesis and metabolism. Curr Opin Cell Biol  2007,19(6),612-617","journal-title":"Curr Opin Cell Biol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1210\/me.2004-0259","volume":"18","author":"Hou X.","year":"2004","unstructured":"Hou X.; Tan Y.; Li M.; Dey S.K.; Das S.K.; Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrinol  2004,18(12),3035-3049","journal-title":"Mol Endocrinol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"17053","DOI":"10.1073\/pnas.1313650110","volume":"110","author":"Ono M.","year":"2013","unstructured":"Ono M.; Yin P.; Navarro A.; Moravek M.B.; Coon J.S.; Druschitz S.A.; Serna V.A.; Qiang W.; Brooks D.C.; Malpani S.S.; Ma J.; Ercan C.M.; Mittal N.; Monsivais D.; Dyson M.T.; Yemelyanov A.; Maruyama T.; Chakravarti D.; Kim J.J.; Kurita T.; Gottardi C.J.; Bulun S.E.; Paracrine activation of WNT\/\u03b2-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA  2013,110(42),17053-17058","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4236\/ojmc.2012.24017","volume":"2","author":"Kore P.P.","year":"2012","unstructured":"Kore P.P.; Mutha M.M.; Antre R.V.; Oswal R.J.; Kshirsagar S.S.; Computer-aided drug design: an innovative tool for modeling. Open J Med Chem  2012,2(4),139-148","journal-title":"Open J Med Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.30574\/gscbps.2018.4.3.0065.","volume":"4","author":"Wulandari F.","year":"2018","unstructured":"Wulandari F.; Aryani L.; Isworo S. J. G. B.; Sciences P.; Utilization of bamboo water plant ( Equisetum hyemale ) in reducing chemical oxygen demand level of laboratory waste.  2018,4(3),18-023"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","volume":"1607","author":"Burley S.K.","year":"2017","unstructured":"Burley S.K.; Berman H.M.; Kleywegt G.J.; Markley J.L.; Nakamura H.; Velankar S.; Protein Data Bank (PDB): The single Global Macromolecular structure Archive. Methods Mol Biol  2017,1607,627-641","journal-title":"Methods Mol Biol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"Pettersen E.F.","year":"2021","unstructured":"Pettersen E.F.; Goddard T.D.; Huang C.C.; Meng E.C.; Couch G.S.; Croll T.I.; Morris J.H.; Ferrin T.E.; UCSF ChimeraX : Structure visualization for researchers, educators, and developers. Protein Sci  2021,30(1),70-82","journal-title":"Protein Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"W363","DOI":"10.1093\/nar\/gky473","volume":"46","author":"Tian W.","year":"2018","unstructured":"Tian W.; Chen C.; Lei X.; Zhao J.; Liang J.; CASTp 3.0: computed atlas of surface topography of proteins. Nucleic Acids Res  2018,46(W1),W363-W367","journal-title":"Nucleic Acids Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e1298","DOI":"10.1002\/wcms.1298","volume":"7","author":"Yuan S.","year":"2017","unstructured":"Yuan S.; Chan H.C.S.; Hu Z.; Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci  2017,7(2),e1298","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"D1373","DOI":"10.1093\/nar\/gkac956","volume":"51","author":"Kim S.","year":"2023","unstructured":"Kim S.; Chen J.; Cheng T.; Gindulyte A.; He J.; He S.; Li Q.; Shoemaker B.A.; Thiessen P.A.; Yu B.; Zaslavsky L.; Zhang J.; Bolton E.E.; PubChem 2023 update. Nucleic Acids Res  2023,51(D1),D1373-D1380","journal-title":"Nucleic Acids Res"},{"key":"ref=42","first-page":"41","volume":"2017","author":"Ounthaisong U.","year":"2017","unstructured":"Ounthaisong U.; Tangyuenyongwatana P.; Cross-docking study of flavonoids against tyrosinase enzymes using PyRx 0.8 virtual screening tool. TJPS  2017,2017,41","journal-title":"TJPS"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1080\/07391102.2020.1765876","volume":"39","author":"Adeoye A.O.","year":"2021","unstructured":"Adeoye A.O.; Oso B.J.; Olaoye I.F.; Tijjani H.; Adebayo A.I.; Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus. J Biomol Struct Dyn  2021,39(10),3469-3479","journal-title":"J Biomol Struct Dyn"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19.","volume":"1263","author":"Dallakyan S.","year":"2015","unstructured":"Dallakyan S.; Olson A. J.; Small-molecule library screening by docking with PyRx. Methods Mol Biol  2015,1263,243-50","journal-title":"Methods Mol Biol"},{"key":"ref=45","first-page":"14","volume":"Chapter 8","author":"Morris G.M.","year":"2008","unstructured":"Morris G.M.; Huey R.; Olson A.J.; Using AutoDock for ligand-receptor docking. Curr Protoc Bioinformatics  2008,Chapter 8(1),14","journal-title":"Curr Protoc Bioinformatics"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/978-1-4939-9752-7_12.","volume":"2053","author":"Bitencourt-Ferreira G.","year":"2019","unstructured":"Bitencourt-Ferreira G.; de Azevedo W. F.; Docking with SwissDock. Methods Mol Biol  2019,2053,189-202","journal-title":"Methods Mol Biol"},{"key":"ref=47","year":"2008","unstructured":"BIOVIA. Discoverey studio visualizer  Available from:  https:\/\/discover.3ds.com\/discovery-studio-visualizer-download.2008"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"Goddard T.D.","year":"2018","unstructured":"Goddard T.D.; Huang C.C.; Meng E.C.; Pettersen E.F.; Couch G.S.; Morris J.H.; Ferrin T.E.; UCSF ChimeraX: Meeting modern challenges in visualization and analysis. Protein Sci  2018,27(1),14-25","journal-title":"Protein Sci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3390\/ph15040414","volume":"15","author":"Noor F.","year":"2022","unstructured":"Noor F.; Rehman A.; Ashfaq U.A.; Saleem M.H.; Okla M.K.; Al-Hashimi A.; AbdElgawad H.; Aslam S.; Integrating network pharmacology and molecular docking approaches to decipher the multi-target pharmacological mechanism of Abrus precatorius L. acting on diabetes. Pharmaceuticals (Basel)  2022,15(4),414","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"106290","DOI":"10.1016\/j.compbiomed.2022.106290","volume":"151","author":"Rehman A.","year":"2022","unstructured":"Rehman A.; Noor F.; Fatima I.; Qasim M.; Liao M.; Identification of molecular mechanisms underlying the therapeutic effects of Celosia cristata on immunoglobulin nephropathy. Comput Biol Med  2022,151(Pt A),106290","journal-title":"Comput Biol Med"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/B978-0-12-394296-8.00013-0","author":"Westhouse R.A.","year":"2013","unstructured":"Westhouse R.A.; Car B.D.; Pharmacokinetics and safety assessment. Cancer Immunotherapy  2013,187-206","journal-title":"Cancer Immunotherapy"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"bbad120","DOI":"10.1093\/bib\/bbad120","volume":"24","author":"Noor F.","year":"2023","unstructured":"Noor F.; Asif M.; Ashfaq U.A.; Qasim M.; Tahir ul Qamar M.; Machine learning for synergistic network pharmacology: A comprehensive overview. Brief Bioinform  2023,24(3),bbad120","journal-title":"Brief Bioinform"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"Daina A.","year":"2017","unstructured":"Daina A.; Michielin O.; Zoete V.; SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep  2017,7(1),42717","journal-title":"Sci Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"Banerjee P.","year":"2018","unstructured":"Banerjee P.; Eckert A.O.; Schrey A.K.; Preissner R.; ProTox-II: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res  2018,46(W1),W257-W263","journal-title":"Nucleic Acids Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/bioinformatics\/16.8.747","volume":"16","author":"Lagunin A.","year":"2000","unstructured":"Lagunin A.; Stepanchikova A.; Filimonov D.; Poroikov V.; PASS: prediction of activity spectra for biologically active substances. Bioinformatics  2000,16(8),747-748","journal-title":"Bioinformatics"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1038\/s41598-021-83626-x","volume":"11","author":"Opo F.A.D.M.","year":"2021","unstructured":"Opo F.A.D.M.; Rahman M.M.; Ahammad F.; Ahmed I.; Bhuiyan M.A.; Asiri A.M.; Structure based pharmacophore modeling, virtual screening, molecular docking and ADMET approaches for identification of natural anti- cancer agents targeting XIAP protein. Sci Rep  2021,11(1),4049","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1145\/1188455.1188544","author":"Bowers K.J.","year":"2006","unstructured":"Bowers K.J.; Chow E.; Xu H.; Dror R.O.; Eastwood M.P.; Gregersen B.A.; Klepeis J.L.; Kolossvary I.; Moraes M.A.; Sacerdoti F.D.; Scalable algorithms for molecular dynamics simulations on commodity clusters. Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing  2006,84","journal-title":"Proceedings of the 2006 ACM\/IEEE Conference on Supercomputing"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"bbab098","DOI":"10.1093\/bib\/bbab098","volume":"22","author":"Ahammad F.","year":"2021","unstructured":"Ahammad F.; Alam R.; Mahmud R.; Akhter S.; Talukder E.K.; Tonmoy A.M.; Fahim S.; Al-Ghamdi K.; Samad A.; Qadri I.; Pharmacoinformatics and molecular dynamics simulation-based phytochemical screening of neem plant (Azadiractha indica) against human cancer by targeting MCM7 protein. Brief Bioinform  2021,22(5),bbab098","journal-title":"Brief Bioinform"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"Genheden S.","year":"2015","unstructured":"Genheden S.; Ryde U.; The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov  2015,10(5),449-461","journal-title":"Expert Opin Drug Discov"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/978-1-4939-6798-8_14.","volume":"1561","author":"Bhachoo J.","year":"2017","unstructured":"Bhachoo J.; Beuming T.; Investigating protein-peptide interactions using the schr\u00f6dinger computational suite. Methods Mol Biol  2017,1561,235-254","journal-title":"Methods Mol Biol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/prot.10286","volume":"50","author":"Lovell S.C.","year":"2003","unstructured":"Lovell S.C.; Davis I.W.; Arendall W.B.; de Bakker P.I.W.; Word J.M.; Prisant M.G.; Richardson J.S.; Richardson D.C.; Structure validation by C\u03b1 geometry: \u03d5,\u03c8 and C\u03b2 deviation. Proteins  2003,50(3),437-450","journal-title":"Proteins"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.82860","author":"Koparde A.A.","year":"2018","unstructured":"Koparde A.A.; Doijad R.C.; Magdum C.S.; Natural products in drug discovery. Pharmacognosy-Medicinal plants  2018","journal-title":"Pharmacognosy-Medicinal plants"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/omi.2021.0107","volume":"25","author":"Anjum F.","year":"2021","unstructured":"Anjum F.; Mohammad T.; Almalki A.A.; Akhtar O.; Abdullaev B.; Hassan M.I.; Phytoconstituents and medicinal plants for anticancer drug discovery: Computational identification of potent inhibitors of PIM1 kinase. OMICS  2021,25(9),580-590","journal-title":"OMICS"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"Morice P.","year":"2016","unstructured":"Morice P.; Leary A.; Creutzberg C.; Abu-Rustum N.; Darai E.; Endometrial cancer. Lancet  2016,387(10023),1094-1108","journal-title":"Lancet"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1514010","volume":"383","author":"Lu K.H.","year":"2020","unstructured":"Lu K.H.; Broaddus R.R.; Endometrial Cancer. N Engl J Med  2020,383(21),2053-2064","journal-title":"N Engl J Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"Madhavi Sastry G.","year":"2013","unstructured":"Madhavi Sastry G.; Adzhigirey M.; Day T.; Annabhimoju R.; Sherman W.; Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des  2013,27(3),221-234","journal-title":"J Comput Aided Mol Des"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1007\/s12272-015-0640-5","volume":"38","author":"Macalino S.J.Y.","year":"2015","unstructured":"Macalino S.J.Y.; Gosu V.; Hong S.; Choi S.; Role of computer-aided drug design in modern drug discovery. Arch Pharm Res  2015,38(9),1686-1701","journal-title":"Arch Pharm Res"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-61779-012-6_2.","volume":"716","author":"Zhang S.","year":"2011","unstructured":"Zhang S.; Computer-aided drug discovery and development. Methods Mol Biol  2011,716,23-38","journal-title":"Methods Mol Biol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.drudis.2019.10.014","volume":"25","author":"Jia C.Y.","year":"2020","unstructured":"Jia C.Y.; Li J.Y.; Hao G.F.; Yang G.F.; A drug-likeness toolbox facilitates ADMET study in drug discovery. Drug Discov Today  2020,25(1),248-258","journal-title":"Drug Discov Today"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1359-6446(01)01712-3","volume":"6","author":"Li A.P.","year":"2001","unstructured":"Li A.P.; Screening for human ADME\/Tox drug properties in drug discovery. Drug Discov Today  2001,6(7),357-366","journal-title":"Drug Discov Today"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.microc.2019.01.030","volume":"146","author":"Chmiel T.","year":"2019","unstructured":"Chmiel T.; Mieszkowska A.; Kempi\u0144ska-Kupczyk D.; Kot-Wasik A.; Namie\u015bnik J.; Mazerska Z.; The impact of lipophilicity on environmental processes, drug delivery and bioavailability of food components. Microchem J  2019,146,393-406","journal-title":"Microchem J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/cmdc.200600155","volume":"1","author":"Norinder U.","year":"2006","unstructured":"Norinder U.; Bergstr\u00f6m C.A.S.; Prediction of ADMET Properties. ChemMedChem  2006,1(9),920-937","journal-title":"ChemMedChem"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.drudis.2014.01.006","volume":"19","author":"Segall M.D.","year":"2014","unstructured":"Segall M.D.; Barber C.; Addressing toxicity risk when designing and selecting compounds in early drug discovery. Drug Discov Today  2014,19(5),688-693","journal-title":"Drug Discov Today"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.taap.2009.08.022","volume":"241","author":"Valerio L.G.","year":"2009","unstructured":"Valerio L.G.; In silico toxicology for the pharmaceutical sciences. Toxicol Appl Pharmacol  2009,241(3),356-370","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/wcms.1240","volume":"6","author":"Raies A.B.","year":"2016","unstructured":"Raies A.B.; Bajic V.B.; In silico toxicology: Computational methods for the prediction of chemical toxicity. Wiley Interdiscip Rev Comput Mol Sci  2016,6(2),147-172","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1517\/14740338.7.2.107","volume":"7","author":"Fielden M.R.","year":"2008","unstructured":"Fielden M.R.; Kolaja K.L.; The role of early in vivo toxicity testing in drug discovery toxicology. Expert Opin Drug Saf  2008,7(2),107-110","journal-title":"Expert Opin Drug Saf"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1021\/ci100275a","volume":"51","author":"Hou T.","year":"2011","unstructured":"Hou T.; Wang J.; Li Y.; Wang W.; Assessing the performance of the MM\/PBSA and MM\/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations. J Chem Inf Model  2011,51(1),69-82","journal-title":"J Chem Inf Model"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"107424","DOI":"10.1016\/j.compbiomed.2023.107424","volume":"165","author":"Rehman A.","year":"2023","unstructured":"Rehman A.; Fatima I.; Wang Y.; Tong J.; Noor F.; Qasim M.; Peng Y.; Liao M.; Unveiling the multi-target compounds of Rhazya stricta : Discovery and inhibition of novel target genes for the treatment of clear cell renal cell carcinoma. Comput Biol Med  2023,165,107424","journal-title":"Comput Biol Med"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673307257240826111754","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/234353\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673307257240826111754","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:03:48Z","timestamp":1772435028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/234353\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673307257240826111754","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-30","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}